RxDoctor Payments Data

Nicole Vasinko, PA

Medical · Indiana, PANPI 1245600337

Payments from drug & device makers

$1,758in general payments, 2019–2025

Across 65 payments — averaging $27.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$480
  • AbbVie$402
  • Lundbeck LLC$288
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$283
  • Otsuka America Pharmaceutical, Inc.$154
  • Neurocrine Biosciences, Inc.$65
  • plus $86 from 2 others

What the payments were for

  • Food & beverage$1,48885%
  • Education$27015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,758 in reported general payments places this provider in the 75th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$8,941
Medicare patients
20
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine16$85,064
VraylarCariprazine Hcl37$53,156
Abilify MaintenaAripiprazole21$52,427
LatudaLurasidone Hcl20$28,544
Invega SustennaPaliperidone Palmitate11$27,913
RexultiBrexpiprazole18$25,149
CaplytaLumateperone Tosylate12$20,605
SeroquelQuetiapine Fumarate13$20,277
Chlorpromazine Hcl22$9,528
Paliperidone ErPaliperidone14$7,735
Buspirone Hcl278$6,521
Aripiprazole97$5,389
Clozapine51$2,970
Bupropion XlBupropion Hcl199$2,606
Quetiapine Fumarate152$2,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$480$85,06416 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$154$77,57639 claims
AbbVieVraylar$402$53,15637 claims
Sunovion Pharmaceuticals Inc.Latuda$24$28,54420 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$283$20,60512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Indiana

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →